Cytomegalovirus resistance in CD34⁺ -selected hematopoietic cell transplant recipients.

ABSTRACT:

Background

Cytomegalovirus (CMV) viremia after CD34⁺ -selected hematopoietic stem cell transplant (HCT) often requires prolonged antiviral therapy. We report rates and outcomes of resistant CMV in a contemporary cohort of CD34⁺ -selected HCT recipients managed preemptively.

Methods

We retrospectively reviewed 220 consecutive, CMV-seropositive recipients (R+), who received CD34⁺ -selected HCT at Memorial Sloan Kettering Cancer Center between June 2010 and December 2014. Patients were monitored by quantitative CMV PCR and were treated preemptively. CMV resistance was tested by a genotypic assay.

Results

One hundred and sixty-one (73%) patients developed CMV viremia and 47 (29% of viremic and 21% of total patients) had CMV resistance test

SUBMITTER: Kim SJ 

PROVIDER: S-EPMC5988949 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature